Prognostic value of ESR2 expression on adjuvant chemotherapy in completely resected NSCLC.

ABSTRACT:

Background

Prognostic biomarker, which can inform the treatment outcome of adjuvant chemotherapy (ACT) after complete resection of early-stage non-small cell lung cancer (NSCLC), is urgently needed for the personalized treatment of these patients.

Patients and methods

The prognostic value of gene expression of the estrogen receptor (ER) on the effect of ACT in completely resected NSCLC was investigated in the present study. Two independent datasets from Gene Expression Omnibus (GEO) with a total of 309 patients were included in this study. The prognostic value of ER gene expression on ACT's efficacy was evaluated by survival analysis and Cox hazards models.

Results

We found a consistent and significant prognostic value of ERβ (ESR2) expression for ACT's efficacy in co

SUBMITTER: Yu H 

PROVIDER: S-EPMC7746143 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature